ReviewEndocrine reviews2013
Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals.
Review in Endocrine reviews, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
103 citing papers in PubMed, 5 syntheses or guidelines pooled it, 264 citations in OpenAlex.
- Genetic evidence for the causal association between type 1 diabetes and the risk of polycystic ovary syndrome.Human genomics · 2023Pooled it
- Effects of Coffee Supplementation on Homocysteine and Leptin Levels: A Systematic Review and Meta-analysis of Clinical Trials.Current pharmaceutical design · 2023Pooled it
- Association between serum leptin levels and breast cancer risk: An updated systematic review and meta-analysis.Medicine · 2018Pooled it
- Clinical Features and Management of Non-HIV-Related Lipodystrophy in Children: A Systematic Review.The Journal of clinical endocrinology and metabolism · 2017Pooled it
- Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis.Diabetologia · 2016Pooled it
- Metreleptin therapy for nonalcoholic steatohepatitis: Open-label therapy interventions in two different clinical settings.Med (New York, N.Y.) · 2021Trial
- Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.The Journal of clinical endocrinology and metabolism · 2015Trial
- Trial
- Effects of leptin replacement therapy on pancreatic β-cell function in patients with lipodystrophy.Diabetes care · 2014Trial
- Kisspeptin as a test of hypothalamic dysfunction in pubertal and reproductive disorders.Andrology · 2026Review
- Leptin Therapy Improves Metabolic Dysfunction in Immune Checkpoint Inhibitor-induced Lipodystrophy.JCEM case reports · 2026Article
- Research Progress on Leptin in Metabolic Dysfunction-associated Fatty Liver Disease.Journal of clinical and translational hepatology · 2025Review
- An unexpected role for the brain in the pathogenesis of diabetic ketoacidosis.The Journal of clinical investigation · 2025Article
- Hypoglycemia compensation mechanisms in dry fasting.Metabolism open · 2025Article
- The Influence of Metabolic Syndrome on the Development of Gastrointestinal Malignant Tumors-A Review.Medicina (Kaunas, Lithuania) · 2025Review
- Article
- Hypogonadism and nonalcoholic fatty liver disease.Endocrine · 2024Review
- Adipose Tissue Dysfunction and Energy Balance Paradigms in People Living With HIV.Endocrine reviews · 2024Review
- Physiological Appetite Regulation and Bariatric Surgery.Journal of clinical medicine · 2024Review
- Affective and Cognitive Impairments in Rodent Models of Diabetes.Current neuropharmacology · 2024Review
43 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 3 countries.
Funding
Abstract
Leptin is an adipocyte-secreted hormone that has been proposed to regulate energy homeostasis as well as metabolic, reproductive, neuroendocrine, and immune functions. In the context of open-label uncontrolled studies, leptin administration has demonstrated insulin-sensitizing effects in patients with congenital lipodystrophy associated with relative leptin deficiency. Leptin administration has also been shown to decrease central fat mass and improve insulin sensitivity and fasting insulin and glucose levels in HIV-infected patients with highly active antiretroviral therapy (HAART)-induced lipodystrophy, insulin resistance, and leptin deficiency. On the contrary, the effects of leptin treatment in leptin-replete or hyperleptinemic obese individuals with glucose intolerance and diabetes mellitus have been minimal or null, presumably due to leptin tolerance or resistance that impairs leptin action. Similarly, experimental evidence suggests a null or a possibly adverse role of leptin treatment in nonlipodystrophic patients with nonalcoholic fatty liver disease. In this review, we present a description of leptin biology and signaling; we summarize leptin's contribution to glucose metabolism in animals and humans in vitro, ex vivo, and in vivo; and we provide insights into the emerging clinical applications and therapeutic uses of leptin in humans with lipodystrophy and/or diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.